AstraZeneca and MedImmune, its department for global biologics research and development, recently gave 28 presentations at the American Heart Association (AHA) Scientific Sessions, which took place Nov. 11-15 in Anaheim, California.
The presentations, which included reports on two late-breaking trials, focused on the company’s goals to help treat cardiovascular, renal and metabolic diseases (CVMD), according to an AstraZeneca press release.
“With the breadth of our scientific updates at AHA 2017, we are at the forefront of the clinical debate, exploring the often unseen but vital connections between cardiovascular, renal and metabolic diseases,” Ludovic Helfgott, vice president of cardiovascular and metabolic diseases, said in the release. “This approach embodies our commitment to improving outcomes for patients while reducing long-term morbidity and mortality.”
AstraZeneca noted that the key data at the presentations revolved around the China-based study Efficacy of Different Antiplatelet Therapy Strategy after Coronary Artery Bypass Grafting (DACAB) and the Exenatide Study of Cardiovascular Event Lowering (EXSCEL) trial. The company also discussed potential new CVMD medicines, the release said.
The DACAB study examines the effects of Brilinta plus aspirin for use following elective coronary artery bypass graft surgery. The EXSCEL clinical trial aims to showcase Bydureon as a once-weekly treatment for patients with Type 2 diabetes.
